Citable filing context
RVTY's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Revvity reported Q2 2026 revenue of $730 million and entered an agreement to divest its China IDX business. |
| May 5, 2026 | earnings | Revvity reported Q1 2026 revenue of $711 million and announced the divestiture of its China Immunodiagnostics business. |
| May 1, 2026 | other | Shareholders approved a by-law amendment allowing owners of 25% of stock to call special meetings. |
| Aug 4, 2026 | Guidance: pro_forma_adjusted_eps | 5.30 to 5.40 |
| Aug 4, 2026 | Guidance: pro_forma_organic_revenue_growth | 4.00 to 5.00 |
| Aug 4, 2026 | Guidance: revenue | 2.83 to 2.86 |
| Aug 11, 2026 | mda_quarterly | Revvity’s second quarter 2026 revenue reached $729.7 million, a 1% year-over-year increase. The Diagnostics segment grew 5% to $371.0 million, driven by strength in Reproductive Health, while the Life Sciences segment declined 2% to $358.7 million due to lower software revenue. Consolidated gross margins expanded 260 basis points to 57.1%, bolstered by $16.2 million in tariff refunds and favorable product mix. However, operating margins contracted to 12.2% from 12.6%, primarily due to increased restructuring charges—which affected 3% of the workforce in the quarter—and ongoing digital investments. Liquidity remains stable with $1.02 billion in cash and $1.5 billion in available revolving credit. The company continues to execute its capital allocation strategy, repurchasing $86.9 million in common stock during the first half of 2026, with $792.7 million remaining under its current authorization. Strategic activity included the $72 million acquisition of ACD/Labs to bolster scientific software capabilities. Subsequent to the quarter, Revvity announced a definitive agreement to divest its Immunodiagnostics business in China, which accounted for approximately 6% of 2025 revenue. Management expects an effective tax rate of approximately 20% for fiscal year 2026 and maintains that internal operations will sufficiently fund near-term capital requirements and debt obligations. |
| May 12, 2026 | mda_quarterly | Revvity reported first-quarter fiscal 2026 revenue of $711.1 million, a 7% increase year-over-year. Growth was driven by the Diagnostics segment, which rose 8% due to Reproductive Health and favorable foreign exchange, and the Life Sciences segment, which grew 6% via Life Sciences Solutions and Software. Despite revenue growth, consolidated gross margins contracted 200 basis points to 54.5%, pressured by product mix shifts, foreign exchange, and approximately $8 million in tariff costs. Operating margins slightly declined to 10.7%, partially offset by cost containment initiatives. Strategic expansion included the $72 million acquisition of ACD/Labs to enhance scientific software capabilities for pharmaceutical and material sciences. To streamline operations, the company incurred $10.7 million in restructuring charges, including workforce reductions affecting 2% of employees. Liquidity remains stable with $860.3 million in cash and a $1.5 billion revolving credit facility, though the company must address the maturity of €500 million in Senior Unsecured Notes in July 2026. Capital allocation focused on shareholder returns, with $79 million in share repurchases during the quarter and a maintained quarterly dividend of $0.07 per share. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
RVTY company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.